Showing posts with label biomarker. Show all posts
Showing posts with label biomarker. Show all posts

Wednesday, January 30, 2013

High Calcium may Flag Ovarian Cancer


High Calcium may Flag Ovarian Cancer


Tuesday - January 29, 2013

Nick Tate

In a groundbreaking new study, researchers from Wake Forest Baptist Medical Center have found high blood calcium levels might flag ovarian cancer — the most lethal of the gynecologic cancers.

The finding, published online in the journal Gynecologic Oncology, could point the way to a new way to predict women who may be at greater risk of developing ovarian cancer, which is often diagnosed late when it is harder to treat.

Lead researcher Gary G. Schwartz, a cancer epidemiologist at Wake Forest Baptist, made the connection by examining associations between blood calcium and ovarian cancer in two groups of cancer patients. Schwartz and co-researcher Halcyon G. Skinner, of the University of Wisconsin Carbone Cancer Center, found women who were later diagnosed with ovarian cancer and women who later died of ovarian cancer had higher levels of calcium in their blood than women who did not before their cancer diagnosis.

Schwartz said the idea for this study sprung from earlier research that showed men with high calcium levels were at increased risk of aggressive prostate cancer. That led him to wonder if a similar relationship were true of ovarian cancer.

"One approach to cancer biomarker discovery is to identify a factor that is differentially expressed in individuals with and without cancer and to examine that factor's ability to detect cancer in an independent sample of individuals," Schwartz said.

"Everyone's got calcium and the body regulates it very tightly," Skinner added. "We know that some rare forms of ovarian cancer are associated with very high calcium, so it's worth considering whether more common ovarian cancers are associated with moderately high calcium."

The researchers explained that tumors in many cancers produce increased levels of a protein — known as PTRHrP (parathyroid hormone-related protein) — that raise calcium levels in blood.

The finding could be particularly significant for patients who develop types of cancer, such as ovarian cancer, that have high fatality rates because they are hard to detect early.

Schwartz said the findings could lead to the use of a calcium biomarker to diagnose ovarian cancer early, but noted more research is needed.

"We found the link between serum calcium and ovarian cancer; we confirmed it, and even though the study is small, we're reporting it because it's a very simple thing in theory to test," he said.

NewsMaxHealth

Saturday, November 3, 2012

HE4 a biomarker of ovarian cancer


HE4 a biomarker of ovarian cancer


Fall 2012

[Article in Czech]

Abstract


Objective: Verification of the importance of determination of HE4 and calculation of ROMA index for increasing the efficiency of diagnosis of ovarian cancer in a population of Czech women.Design: Prospective study.Setting: Department of Gynaecology and Obstetrics, Faculty Hospital in Pilsen.

Methods: In the period from 06/24/2010 to 12/01/2011 was at the Department of Gynaecology and Obstetrics, University Hospital Pilsen examined 552 patients with abnormalities in the pelvis. Patients were divided into two groups. There were 30 women with histologically confirmed malignant ovarian tumors. Another 522 women had benign findings. According to the levels of FSH were women in both groups divided into premenopausal and postmenopausal. At all women were measured CA 125, HE4 and FSH. HE4 and CA125 were determined using the chemiluminescent device Architect 1000 (Abbott, USA), FSH chemiluminescent method on the device DXI 800 (Beckman Coulter, USA). At all premenopausal women was calculated ROMA1 index and at all postmenopausal women ROMA2 index. SAS statistical software 9.2 were used for all statistical calculations.

Results: The highest diagnostic efficiency was achieved by a combination of HE4 and CA125 markers with the calculation ROMA2 index for postmenopausal women. In determining of menopausal status according to the values of FSH cut-off for menopause 40 IU/L and cut-off at 26.4% for ROMA2 reaches ROMA2 sensitivity of 92.3%, specificity of 88.5% and PV- of 99.3%. If we reduce the cut-off for laboratory diagnosis of menopause using FSH at 22 IU/L, and cut-off for ROMA2 was 26.3% reaches ROMA2 sensitivity of 95.2%, specificity of 87.8% and PV- of 99.5%.

Conclusion: HE4 in combination with CA125 and current ROMA index calculation is a suitable methodology to improve the detection of ovarian cancer. Key words: HE4, CA125, ROMA index, ovarian cancer, menopausal status.